Pyxis Oncology (PYXS) Amortizatization of Intangibles (2023 - 2025)
Pyxis Oncology (PYXS) reported Amortizatization of Intangibles of $375000.0 for Q4 2025, down 75.54% year-over-year from $1.5 million in Q4 2024, and down 29.51% on a QoQ basis from $532000.0 in Q3 2025.
Pyxis Oncology (PYXS) has 3 years of Amortizatization of Intangibles data on file, last reported at $375000.0 in Q4 2025.
- Quarterly Amortizatization of Intangibles fell 75.54% year-over-year to $375000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.0 million (down 51.55% YoY) and the FY2025 annual result came in at $3.0 million, down 51.55% from the prior year.
- Amortizatization of Intangibles fell to $375000.0 in Q4 2025 per PYXS's latest filing, from $532000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $1.7 million in Q3 2024 and bottomed at $375000.0 in Q4 2025.
- The 3-year median for Amortizatization of Intangibles is $1.3 million (2023), against an average of $1.2 million.
- The widest annual swing landed in 2024, when Amortizatization of Intangibles jumped 112.19%; it then slumped 75.54% in 2025.
- Tracing PYXS's Amortizatization of Intangibles over 3 years: stood at $1.4 million in 2023, then rose by 6.38% to $1.5 million in 2024, then tumbled by 75.54% to $375000.0 in 2025.
- Per Business Quant, the three latest PYXS Amortizatization of Intangibles figures stand at $375000.0 (Q4 2025), $532000.0 (Q3 2025), and $896000.0 (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 13,267.00 |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | - |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | - |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | - |
| 10 | Pyxis Oncology | 120.87 Mn | 103.97 Mn | 8.65 Mn | 375,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 375,000.00 |
| Dec 31, 2025 | 375,000.00 |
| Sep 30, 2025 | 532,000.00 |
| Sep 30, 2025 | 532,000.00 |
| Jun 30, 2025 | 896,000.00 |
| Jun 30, 2025 | 896,000.00 |
| Mar 31, 2025 | 1.16 Mn |
| Mar 31, 2025 | 1.16 Mn |
| Dec 31, 2024 | 1.53 Mn |
| Dec 31, 2024 | 1.53 Mn |
| Sep 30, 2024 | 1.65 Mn |
| Sep 30, 2024 | 1.65 Mn |
| Jun 30, 2024 | 1.64 Mn |
| Jun 30, 2024 | 1.64 Mn |
| Mar 31, 2024 | 1.29 Mn |
| Mar 31, 2024 | 1.29 Mn |
| Dec 31, 2023 | 1.44 Mn |
| Dec 31, 2023 | 1.44 Mn |
| Sep 30, 2023 | 1.48 Mn |
| Sep 30, 2023 | 1.48 Mn |
| Jun 30, 2023 | 1.26 Mn |
| Jun 30, 2023 | 1.26 Mn |
| Mar 31, 2023 | 607,000.00 |
| Mar 31, 2023 | 607,000.00 |